MoneyWorks4Me

Marksans Pharma reports near three-fold jump in Q1 consolidated net profit

12 Aug 2026 Evaluate

Marksans Pharma has reported results for first quarter ended June 30, 2026 (Q1FY27). 

The company has reported 43.65% jump in its net profit at Rs 69.04 crore for the quarter ended June 30, 2026 as compared to Rs 48.06 crore for the same quarter in the previous year. The total income of the company has increased by 5.26% at Rs 338.66 crore for Q1FY27 as compared to Rs 321.74 crore for the corresponding quarter previous year.

On consolidated basis, the company has reported near three-fold jump in its net profit at Rs 157.17 crore for Q1FY27 as compared to Rs 58.32 crore for the same quarter in the previous year. The total income of the company has increased by 38.45% at Rs 866.20 crore for Q1FY27 as compared to Rs 625.63 crore for the corresponding quarter previous year.

Marksans Pharma Share Price

333.00 29.80 (9.83%)
14-Aug-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma. Inds. 1924.90
Dr. Reddys Labs. 1202.00
Cipla 1450.00
Lupin 2235.00
Zydus Lifesciences 1140.00
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through: